More Post from the Author
- Thomson Reuters Files Documents for Proposed Return of Capital and Share Consolidation Transactions
- [MWC 2026] GSMA zverejnila pecifikciu pouvateskho zitku pre natvne AI aplikcie na telefonovanie
- Newgen lleva a cabo una sesin de debate ejecutiva de alto impacto en Guyana para dar forma al futuro de la inteligencia de decisiones basada en IA
- Payoneer and FundPark Collaborate to Expand Dynamic, Frictionless Credit Access for Global E-Commerce Sellers
- R.H. Boyd Celebrates 130 Years of Legacy, Learning, and Leadership
Indivior Statement RE: Delayed FDA Approval of SUBLOCADE Label Changes
Published on Wed 12 Feb 2025 8:07:04 UTC
RICHMOND, Va., Feb. 12, 2025 /PRNewswire/ --Indivior PLC (Nasdaq/LSE: INDV)provides the following update regarding its PDUFA action date for label changes (rapid initiation protocol and alternative injection sites) for SUBLOCADE (buprenorphine extended-release) Injection, which was scheduled for February 7, 2025:
Yesterday, February 11th, the FDA informed Indivior that, following acceptance of the proposed label for SUBLOCADE, there were no outstanding items to address, but that final review of the SUBLOCADE label changes has been delayed.
Indivior will provide further updates on the status of the approval of the proposed SUBLOCADE label changes as appropriate.
SOURCE Indivior PLC
More Post from the Author
- Thomson Reuters Files Documents for Proposed Return of Capital and Share Consolidation Transactions
- [MWC 2026] GSMA zverejnila pecifikciu pouvateskho zitku pre natvne AI aplikcie na telefonovanie
- Newgen lleva a cabo una sesin de debate ejecutiva de alto impacto en Guyana para dar forma al futuro de la inteligencia de decisiones basada en IA
- Payoneer and FundPark Collaborate to Expand Dynamic, Frictionless Credit Access for Global E-Commerce Sellers
- R.H. Boyd Celebrates 130 Years of Legacy, Learning, and Leadership